Has the recently published SELECT trial of adjuvant erlotinib in early stage EGFR-mutant NSCLC impacted your management of these patients?

The SELECT trial was a well conducted single arm trial of post-operative adjuvant erlotinib in early stage patients with NSCLC bearing an activating EGFR mutation. Compared with historical controls with and without EGFR mutations, the disease free and overall survival were superior. The study establ...